Serum 27-nor-5β-Cholestane-3,7,12,24,25 Pentol Glucuronide Discovered by Metabolomics as Potential Diagnostic Biomarker for Epithelium Ovarian Cancer

Chen, Jing; Zhang, Xiaoyan; Cao, Rui; Lü, Xin; Zhao, Sumin; Fekete, Ágnes; Huang, Qiang; Schmitt‐Kopplin, Philippe; Wang, Yisheng; Xu, Zhiliang; Wan, Xiaoping; Wu, Xiaohua; Zhao, Ning; Xu, Congjian; Xu, Guowang

doi:10.1021/pr200173q

Cited by 85 publications

(78 citation statements)

References 42 publications

(54 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Before analyzing the sample sequence, five QC samples were run. During analysis of the sample sequence, one QC sample was run after every 10 injections, which is similar to our previous method (15).…”

Section: Metabolic Profiling Analysismentioning

confidence: 99%

Metabolic Characterization of Hepatocellular Carcinoma Using Nontargeted Tissue Metabolomics

et al. 2013

Self Cite

View full text Add to dashboard Cite

Hepatocellular carcinoma has a poor prognosis due to its rapid development and early metastasis. In this report, we characterized the metabolic features of hepatocellular carcinoma using a nontargeted metabolic profiling strategy based on liquid chromatography-mass spectrometry. Fifty pairs of liver cancer samples and matched normal tissues were collected from patients having hepatocellular carcinoma, including tumor tissues, adjacent noncancerous tissues, and distal noncancerous tissues, and 105 metabolites were filtered and identified from the tissue metabolome. The principal metabolic alternations in HCC tumors included elevated glycolysis, gluconeogenesis, and b-oxidation with reduced tricarboxylic acid cycle and D-12 desaturase. Furthermore, increased levels of glutathione and other antioxidative molecules, together with decreased levels of inflammatory-related polyunsaturated fatty acids and phospholipase A2, were observed. Differential metabolite levels in tissues were tested in 298 serum specimens from patients with chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Betaine and propionylcarnitine were confirmed to confer good diagnostic potential to distinguish hepatocellular carcinoma from chronic hepatitis and cirrhosis. External validation of cirrhosis and hepatocellular carcinoma serum specimens further showed that this combination biomarker is useful for diagnosis of hepatocellular carcinoma with a supplementary role to a-fetoprotein. Cancer Res; 73(16); 4992-5002. Ó2013 AACR.

show abstract

Section: Metabolic Profiling Analysismentioning

confidence: 99%

Metabolic Characterization of Hepatocellular Carcinoma Using Nontargeted Tissue Metabolomics

et al. 2013

Self Cite

View full text Add to dashboard Cite

show abstract

“…Supporting this hypothesis, Chen et al tentatively detected decreased levels of bilirubin in the serum of both earlyand late-stage EOC patients and increased levels of bilirubin mono-and diglucuronic acids. 21 …”

Section: Sphingoid Basesmentioning

confidence: 99%

Metabolomic Serum Profiling Detects Early-Stage High-Grade Serous Ovarian Cancer in a Mouse Model

Jones

Monge

Kim³

et al. 2015

J. Proteome Res.

View full text Add to dashboard Cite

Ovarian cancer is a deadly disease killing more than any other gynecologic cancer. Nonspecific symptoms, combined with a lack of early detection methods, contribute to late diagnosis and low five-year survival rates. High-grade serous carcinoma (HGSC) is the most common and deadliest subtype that results in 90% of ovarian cancer deaths. To investigate metabolic patterns for early detection of this deadly ovarian cancer, Dicer-Pten double knockout (DKO) mice that phenocopy many of the features of metastatic HGSC observed in women were studied. Using ultraperformance liquid chromatography-mass spectrometry (UPLC-MS), serum samples from 14 early-stage tumor (ET) DKO mice and 11 controls were analyzed in depth to screen for metabolic signatures capable of differentiating early-stage HGSC from controls. Iterative multivariate classification selected 18 metabolites that, when considered as a panel, yielded 100% accuracy, sensitivity, and specificity for classification. Altered metabolic pathways reflected in that panel included those of fatty acids, bile acids, glycerophospholipids, peptides, and some dietary phytochemicals. These alterations revealed impacts to cellular energy storage and membrane stability, as well as changes in defenses against oxidative stress, shedding new light on the metabolic alterations associated with early ovarian cancer stages.

show abstract

“…In particular tissue CPG level was significantly higher in EOC tissue compared with BOT tissue and increased CPG level was found in early stages of EOC and in all of its three histological types. For this reason CPG was considered to be complementary to CA125 and a relevant biomarker for detection of early stages of EOC [72]. UPLC-MS metabonomics has also been applied to differentiate between EOC and BOT.…”

Section: Ovarian Cancermentioning

confidence: 99%

UPLC-based metabonomic applications for discovering biomarkers of diseases in clinical chemistry

Zhao

Cheng

Vaziri

et al. 2014

Clinical Biochemistry

118

View full text Add to dashboard Cite

a b s t r a c t a r t i c l e i n f oObjectives: Metabonomics is a powerful and promising analytic tool that allows assessment of global lowmolecular-weight metabolites in biological systems. It has a great potential for identifying useful biomarkers for early diagnosis, prognosis and assessment of therapeutic interventions in clinical practice. The aim of this review is to provide a brief summary of the recent advances in UPLC-based metabonomic approach for biomarker discovery in a variety of diseases, and to discuss their significance in clinical chemistry.Design and methods: All the available information on UPLC-based metabonomic applications for discovering biomarkers of diseases were collected via a library and electronic search (using Web of Science, Pubmed, ScienceDirect, Springer, Google Scholar, etc.).Results: Metabonomics has been used in clinical chemistry to identify and evaluate potential biomarkers and therapeutic targets in various diseases affecting the liver (hepatocarcinoma and liver cirrhosis), lung (lung cancer and pneumonia), gastrointestinal tract (colorectal cancer) and urogenital tract (prostate cancer, ovarian cancer and chronic kidney disease), as well as metabolic diseases (diabetes) and neuropsychiatric disorders (Alzheimer's disease and schizophrenia), etc.Conclusions: The information provided highlights the potential value of determination of endogenous lowmolecular-weight metabolites and the advantages and potential drawbacks of the application of UPLC-based metabonomics in clinical setting.

show abstract

Serum 27-nor-5β-Cholestane-3,7,12,24,25 Pentol Glucuronide Discovered by Metabolomics as Potential Diagnostic Biomarker for Epithelium Ovarian Cancer

Cited by 85 publications

References 42 publications

Metabolic Characterization of Hepatocellular Carcinoma Using Nontargeted Tissue Metabolomics

Metabolic Characterization of Hepatocellular Carcinoma Using Nontargeted Tissue Metabolomics

Metabolomic Serum Profiling Detects Early-Stage High-Grade Serous Ovarian Cancer in a Mouse Model

UPLC-based metabonomic applications for discovering biomarkers of diseases in clinical chemistry

Contact Info

Product

Resources

About